ARTEMIS clinical trial offers triple-negative patients personalized therapy
Triple-negative breast cancer (TNBC) makes up 15 to 20 percent of breast cancer diagnoses. The condition often is considered a single disease, when in reality, TNBC is a catch-all diagnosis of biologically different breast cancer subtypes that lack expression of estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor receptor 2 (HER2).
In patients with localized disease, a neoadjuvant chemotherapy...
Possible side effects of immunotherapy ¡ª and how to handle them
Over the past decade, immune checkpoint inhibitors have shown success in treating several types of cancer, including melanoma, non-small cell...
Biomarker predicts response to pancreatic cancer therapy
MD Anderson researchers have discovered that a protein called angiogenin (ANG) serves as a potential biomarker useful for stratifying pancreatic...
Potential biomarker linked to better outcomes in acute myeloid leukemia
Somatic mutations in certain genes may function as a molecular minimal residual disease marker for acute myeloid leukemia (AML), according to a study led by Koichi Takahashi, M.D., assistant professor of Leukemia at MD Anderson. The study showed that clearance of somatic mutation at complete response, particularly in non-preleukemic genes, is associated with significantly better overall survival (OS) and cumulative incidence of relapse...
